Tag Archives: PD-1

Constructing a Novel Signature Based on Immune-Related lncRNA to Improve Prognosis Prediction of Cervical Squamous Cell Carcinoma Patients

Researchers assessed the correlation between immune infiltration status, chemotherapeutics sensitivity, immune checkpoint proteins, and the signature.
[Reproductive Sciences]
[zotpress userid=” items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Abstract
Bookmark

No account yet? Register

Share

OSE Immunotherapeutics Receives First Notice of Allowance of a Patent for Use of Tedopi® after Failure with PD-1 or PD-L1 Immune Checkpoint Inhibitor Treatment in HLA-A2 Positive Cancer Patients

OSE Immunotherapeutics SA announced that the Japanese Patent Office has issued the notice of allowance for a new patent covering Tedopi®, a combination of neoepitopes, for use after failure with PD-1 or PD-L1 immune checkpoint inhibitor treatment in HLA-A2 positive cancer patients.
[OSE Immunotherapeutics SA]
[zotpress userid=” items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Press Release
Bookmark

No account yet? Register

Share

Tumor Microenvironment and Its Clinicopathological and Prognostic Associations in Surgically Resected Cutaneous Angiosarcoma

Pretreated specimens were evaluated by immunohistochemistry for programmed cell death protein 1 and its ligand, densities of tumor infiltrative lymphocytes, as well as c-MYC and Ki-67 expressions.
[Clinical and Translational Oncology]
[zotpress userid=” items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Abstract
Bookmark

No account yet? Register

Share

Role of CTLA Inhibition in Management of Non-Small Cell Lung Cancer

The authors review the current role for CTLA-4 inhibitors in early-stage resectable NSCLC, unresectable stage III NSCLC, and in metastatic NSCLC.
[Current Oncology Reports]
[zotpress userid=” items=’SPXSDFJC’ style=’apa’ cite=’yes’]
Abstract
Bookmark

No account yet? Register

Share

Prostate Cancer Immunotherapy

The authors present completed and ongoing research projects regarding prostate cancer immunotherapy. Ipilimumab and olaparib were proved to prolong overall survival significantly against placebo, but a lot of research is going on to identify which patients and at what stage of disease will benefit the most before incorporating them in clinical practice.
[Expert Opinion On Biological Therapy]
[zotpress userid=” items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Abstract
Bookmark

No account yet? Register

Share

Xilio Therapeutics Announces Initiation of Patient Dosing in Phase 1/2 Clinical Trial of XTX202 for the Treatment of Patients with Solid Tumors

Xilio Therapeutics, Inc. announced that the first patient has been dosed in the company’s Phase I/II clinical trial evaluating XTX202 for the treatment of solid tumors. XTX202 is a modified form of IL-2 that is designed to localize activity in the tumor microenvironment.
[Xilio Therapeutics, Inc.]
[zotpress userid=’7992332′ items=’BBBBBBBB’ style=’apa’ cite=’yes’]
Press Release
Bookmark

No account yet? Register

Share

Single‐Cell Immune Mapping of Melanoma Sentinel Lymph Nodes Reveals an Actionable Immunotolerant Microenvironment

Researchers used mass cytometry by time-of-flight, flow cytometry, and T cell receptor immunosequencing to conduct simultaneous single-cell analyses of immune cells in the sentinel lymph nodes of melanoma patients.
[Clinical Cancer Research]
[zotpress userid=” items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Abstract
Bookmark

No account yet? Register

Share

Immuno-Engineered Nanodecoys for the Multi-Target Anti-Inflammatory Treatment of Autoimmune Diseases

IFN-γ treatment induced remarkable PD-L1 expression on PD-L1-expressing macrophage membrane (PRM), thereby allowing PRM nanodecoys to bind mPD-1 on CD4+ T cell surfaces or neutralize free sPD-1, which reconstructed the PD-1/PD-L1 inhibitory axis to suppress CD4+ T cell activation and restore immune tolerance.
[Advanced Materials]
[zotpress userid=” items=’BBBBBBBB’ style=’apa’ cite=’yes’]
Abstract
Bookmark

No account yet? Register

Share

IMV Announces First Patient Dosed in the VITALIZE Phase IIB Clinical Study Evaluating its Lead Compound, MVP-S, in Combination with KEYTRUDA® (pembrolizumab) in Patients with r/r DLBCL

IMV, Inc., a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX platform to treat solid and hematologic cancers, announced a first patient dosed in the VITALIZE Phase IIB clinical trial.
[IMV Inc.]
[zotpress userid=’7992332′ items=’nan’ style=’apa’ cite=’yes’]
Press Release
Bookmark

No account yet? Register

Share

Evaxion Biotech Receives Regulatory Clearance to Initiate Phase II Trial of EVX-01 in Combination with KEYTRUDA® for Treatment of Melanoma

Evaxion Biotech A/S announced it received clearance from the Australia Therapeutic Goods Administration to initiate a Phase IIb trial of its patient specific cancer immunotherapy EVX-01 in combination with Merck & Co., Inc.’s anti-PD-1 therapy KEYTRUDA®.
[Evaxion Biotech A/S]
[zotpress userid=” items=’nan’ style=’apa’ cite=’yes’]
Press Release
Bookmark

No account yet? Register

Share

PD-L1 and PD-L2 Expression in Pancreatic Ductal Adenocarcinoma and Their Correlation with Immune Infiltrates and DNA Damage Response Molecules

The authors investigated the expression of two PD-1 ligands, PD-L1 and PD-L2, in pancreatic ductal adenocarcinoma, analysed their role in survival, and explored their correlation with clinicopathological features, immune infiltration, and DNA damage response molecules.
[Journal of Pathology Clinical Research]
[zotpress userid=” items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share
Share